サンプル依頼リスト カート
  • English
デフォルト表紙
市場調査レポート
商品コード
1757611

リアルワールドエビデンス（RWE）アプリケーションのためのゲノムデータセットの世界市場

Genomic Data Set for Real World Evidence (RWE) Applications

出版日
ページ情報
英文 381 Pages
納期
即日から翌営業日
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=144.69円
リアルワールドエビデンス（RWE）アプリケーションのためのゲノムデータセットの世界市場
出版日: 2025年06月27日
発行: Global Industry Analysts, Inc.
ページ情報: 英文 381 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

リアルワールドエビデンス（RWE）アプリケーションのためのゲノムデータセットの世界市場は2030年までに12億米ドルに達する見込み

2024年に5億3,330万米ドルと推定されるリアルワールドエビデンス（RWE）アプリケーションのためのゲノムデータセットの世界市場は、分析期間2024-2030年にCAGR 15.1％で成長し、2030年には12億米ドルに達すると予測されます。本レポートで分析したセグメントの1つである遺伝子DNAデータは、CAGR17.3%を記録し、分析期間終了時には5億4,740万米ドルに達すると予測されます。トランスクリプトームRNAデータ分野の成長率は、分析期間中CAGR 12.8％と推定されます。

米国市場は1億4,530万米ドルと推定、中国はCAGR20.4%で成長すると予測

米国のリアルワールドエビデンス（RWE）アプリケーションのためのゲノムデータセット市場は、2024年に1億4,530万米ドルと推定されます。世界第2位の経済大国である中国は、分析期間2024-2030年のCAGR 20.4%を牽引し、2030年には2億7,300万米ドルの市場規模に達すると予測されています。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ10.9%と13.7%と予測されています。欧州では、ドイツがCAGR約12.1％で成長すると予測されています。

世界の「リアルワールドエビデンス（RWE）アプリケーションのためのゲノムデータセット」市場- 主要動向と促進要因のまとめ

ゲノムデータセットは実世界のエビデンスの基盤をどのように変革しているか？

リアルワールドエビデンス（RWE）フレームワークにおけるゲノムデータセットの応用は、ライフサイエンス業界がエビデンス創出、規制当局の意思決定、臨床戦略にアプローチする方法を急速に変化させています。従来、RGlobal Industry Analystは、電子カルテ（EHR）、保険請求、患者登録、健康調査などの情報源からの観察データに依存していました。しかし、ゲノムシーケンス、特に次世代シーケンシング（NGS）の飛躍的な成長により、膨大なゲノムデータセットがRGlobal Industry Analystsのプラットフォームに統合され、より生物学的根拠に基づいた、精度を重視したヘルスケアインサイトの基盤が構築されつつあります。このシフトにより、遺伝的変動に基づく疾患病因、患者層別化、治療効果、転帰のより深い理解が可能になります。例えば、ゲノムRGlobal Industry Analystsは、薬剤反応、有害事象、疾患の進行を予測するバイオマーカーの同定に役立っています。バイオ製薬企業や研究機関は、UK Biobank、All of Us Research Program、Genomics Englandなどの大規模集団コホートからリンクされたゲノムデータや表現型データを活用し、実用的なエビデンスを大規模に導き出そうとしています。さらに、世界の医療制度がデジタル化され、精密医療モデルが採用されるにつれて、包括的なゲノムデータセットを実世界で使用することで、観察研究において前例のない可能性が開花し、標的治療の開発が加速され、市場全体における規制や償還戦略の指針となっています。

ゲノムRWEの利用を可能にする技術とインフラの進歩とは？

ゲノムデータのRGlobal Industry Analystsアプリケーションへの統合は、インフラの準備、技術的相互運用性、高度な分析に大きく依存しています。中核となるのは、全ゲノム、全エクソーム、ターゲットシーケンスなど、広範なゲノムプロファイルを生成するハイスループットシーケンスプラットフォームです。これらのゲノムデータセットは、プライバシーを保護するレコードリンケージ技術や、異種データの保存と調和を図るために設計されたクラウドベースのデータレイクを使用して、縦断的な患者データとリンクされます。クラウドインフラ、特にAWS、Google Cloud、Microsoft Azureなどのプロバイダーとの提携により、ゲノムパイプラインへのスケーラブルで安全なアクセスが可能になります。バイオインフォマティクスツールと人工知能アルゴリズムは、この複雑なデータのマイニングの中心であり、遺伝子型-表現型相関の同定、集団特異的バリアント解析、分散化されたデータソースからのリアルタイムのエビデンス生成を可能にします。フェデレーション型学習モデルも支持を集めており、研究機関は保護された環境の外に機密性の高いゲノムデータを移動させることなく、RGlobal Industry Analystsの研究に協力することができます。ゲノム情報のためのFHIR GenomicsやOMOP CDM拡張などの相互運用性標準は、これらのデータをEHR、臨床試験、観察研究に一貫して統合できるようにするために不可欠です。施設レベルでは、ゲノムデータウェアハウスと同意管理フレームワークが、研究や政策立案のための2次利用を促進しながら患者のプライバシーを確保するために導入されています。これらのツールの高度化は、RWEで達成できることの限界を押し広げ、ゲノミクスを将来対応可能なヘルスケアシステムの基礎層として位置づけています。

ヘルスケアとライフサイエンスにおけるゲノムRGlobal Industry Analystsをエンドユーザーはどのように採用しているか？

RGlobal Industry Analystsアプリケーションにおけるゲノムデータセットの採用は、製薬会社、支払者、プロバイダー、規制当局、学術機関を含む幅広いエンドユーザーにわたって拡大しています。医薬品開発では、バイオ製薬会社はゲノムRGlobal Industry Analystsを活用して、ターゲットを絞った患者募集、適応試験モデル、市販後の安全性モニタリングを通じて臨床試験デザインを最適化しています。特定の遺伝子変異が実世界の多様な集団の治療反応にどのような影響を与えるかを分析することで、企業はアンメットニーズをより的確に特定し、関連するエンドポイントを選択し、治療法をより正確に調整することができます。支払者側では、保険会社は価値ベースの契約、適用基準、精密な処方管理に関する決定をサポートするためにゲノムRGlobal Industry Analystsに依存し始めています。病院や医療システムも、特に腫瘍学、希少疾患、薬理ゲノミクスにおいて、診断精度を高め、ケア経路を個別化するために、ゲノムデータを臨床意思決定支援ツールに組み込みつつあります。FDAやEMAのような規制当局は、ゲノム情報に基づくRGlobal Industry Analystsを採用し、追加承認、添付文書拡大、既に市場に出ている医薬品のリスク・ベネフィット評価をサポートしています。さらに、学術研究者は、これらのデータセットを実際の遺伝子と環境の相互作用や集団特有の健康格差の研究に応用しています。実世界のゲノミクスは、感染症変異のサーベイランスやワクチン効果の評価など、公衆衛生ゲノミクスの取り組みにも利用されています。利害関係者の需要、技術的な準備、政策の進化が融合することで、ゲノムRGをヘルスケアの全過程に組み込むという制度的な取り組みが広まりつつあります。

ゲノムRGlobal Analysts市場の成長を促進する主な要因は？

リアルワールドエビデンス（RWE）アプリケーションのためのゲノムデータセット市場の成長は、技術の進歩、ヘルスケアモデルの転換、データアクセシビリティ、エンドユーザーのインセンティブに関連するいくつかの要因によってもたらされます。第一に、ゲノムシークエンシングのコストが劇的に低下したことで、多様な患者コホートの大規模シークエンシングを実施することが可能になり、より代表的で包括的なRGlobal Industry Analysts研究が可能になりました。第二に、価値観に基づくケアと精密医療モデルの台頭により、低コストでより良い転帰をサポートするために遺伝子データを組み込んだ個別化エビデンスに対する強い需要が生まれています。第三に、規制当局がゲノムRGlobal Industry Analystsを市販後調査、早期承認、薬剤再利用のための有効なエビデンスストリームとして認識するようになっており、製薬企業がゲノムで強化された実臨床試験に投資する明確なインセンティブとなっています。もう一つの大きな推進力は、ゲノムプロファイルと生涯健康記録をリンクさせ、観察解析のための豊富なデータ環境を提供する縦断的バイオバンクや国家ゲノムプログラムの普及です。さらに、ゲノム情報に基づく利用管理に対する支払者の関心が、特に腫瘍や希少疾患のような高コストの領域で高まっています。相互運用可能なデータ標準と同意に基づくデータ共有フレームワークの開発も、実世界の研究環境におけるゲノムRGGlobal Industry Analystsの統合と利用を容易にしています。さらに、AIを活用した分析プラットフォームは、実世界の集団におけるマルチオミックデータを用いた、より迅速な洞察とよりダイナミックな仮説検証を可能にしています。最後に、ハイテク企業、医療システム、ライフサイエンス企業間のパートナーシップの世界な拡大が、ゲノムRGlobal Industry Analystsアプリケーションの商業化と実用化を加速させています。これらの要因が相まって、精密医療時代における実世界でのエビデンス生成の基準を再定義する態勢を整えた、強固で拡大する世界市場を牽引しています。

セグメント

データタイプ（遺伝子DNAデータ、トランスクリプトームRNAデータ、プロテオーム蛋白質データ、代謝物データ）、用途（腫瘍学用途、心臓血管系用途、神経学用途、免疫学用途、その他用途）、最終用途（バイオ医薬品最終用途、その他最終用途）

調査対象企業の例（注目の42社）

  • 23andMe
  • Aetion Inc.
  • BC Platforms
  • Caris Life Sciences
  • Cegedim Health Data
  • Citeline
  • Clarify Health
  • Cognizant
  • ConcertAI
  • Cytel Inc.
  • Datavant
  • Epigene Labs
  • Flatiron Health
  • Foundation Medicine, Inc.
  • Genuity Science
  • Guardant Health
  • HealthVerity, Inc.
  • Helix
  • ICarbonX
  • Illumina, Inc.

AI統合

当社は、有効な専門家コンテンツとAIツールにより、市場情報と競合情報を変革しています。

Global Industry Analystsは、LLMや業界固有のSLMを照会する一般的な規範に従う代わりに、ビデオ記録、ブログ、検索エンジン調査、膨大な量の企業、製品/サービス、市場データなど、世界中の専門家から収集したコンテンツのリポジトリを構築しました。

関税影響係数

Global Industry Analystsは、本社の国、製造拠点、輸出入（完成品とOEM）に基づく企業の競争力の変化を予測しています。この複雑で多面的な市場力学は、売上原価（COGS）の増加、収益性の低下、サプライチェーンの再構築など、ミクロおよびマクロの市場力学の中でも特に競合他社に影響を与える見込みです。

目次

第1章 調査手法

第2章 エグゼクティブサマリー

  • 市場概要
  • 主要企業
  • 市場動向と促進要因
  • 世界市場の見通し

第3章 市場分析

  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • スペイン
  • ロシア
  • その他欧州
  • アジア太平洋
  • オーストラリア
  • インド
  • 韓国
  • その他アジア太平洋地域
  • ラテンアメリカ
  • アルゼンチン
  • ブラジル
  • メキシコ
  • その他ラテンアメリカ
  • 中東
  • イラン
  • イスラエル
  • サウジアラビア
  • アラブ首長国連邦
  • その他中東
  • アフリカ

第4章 競合

目次
Product Code: MCP36995

Global Genomic Data Set for Real World Evidence (RWE) Applications Market to Reach US$1.2 Billion by 2030

The global market for Genomic Data Set for Real World Evidence (RWE) Applications estimated at US$533.3 Million in the year 2024, is expected to reach US$1.2 Billion by 2030, growing at a CAGR of 15.1% over the analysis period 2024-2030. Genetic DNA Data, one of the segments analyzed in the report, is expected to record a 17.3% CAGR and reach US$547.4 Million by the end of the analysis period. Growth in the Transcriptome RNA Data segment is estimated at 12.8% CAGR over the analysis period.

The U.S. Market is Estimated at US$145.3 Million While China is Forecast to Grow at 20.4% CAGR

The Genomic Data Set for Real World Evidence (RWE) Applications market in the U.S. is estimated at US$145.3 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$273.0 Million by the year 2030 trailing a CAGR of 20.4% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 10.9% and 13.7% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 12.1% CAGR.

Global "Genomic Data Set for Real World Evidence (RWE) Applications" Market - Key Trends & Drivers Summarized

How Are Genomic Data Sets Transforming the Foundation of Real World Evidence?

The application of genomic data sets in Real World Evidence (RWE) frameworks is rapidly reshaping how the life sciences industry approaches evidence generation, regulatory decision-making, and clinical strategy. Traditionally, RWE relied on observational data from sources such as electronic health records (EHRs), insurance claims, patient registries, and health surveys. However, with the exponential growth of genomic sequencing, especially next-generation sequencing (NGS), vast genomic data sets are being integrated into RWE platforms to create a more biologically anchored, precision-driven foundation for healthcare insights. This shift enables a deeper understanding of disease etiology, patient stratification, treatment efficacy, and outcomes based on genetic variability. For example, genomic RWE is becoming instrumental in identifying biomarkers predictive of drug response, adverse events, and disease progression-information critical for both drug development and clinical practice. Biopharma companies and research institutions are increasingly leveraging linked genomic and phenotypic data from large population cohorts, such as those curated by the UK Biobank, All of Us Research Program, and Genomics England, to derive actionable evidence at scale. Moreover, as global health systems digitize and adopt precision medicine models, the use of comprehensive genomic data sets in real-world contexts is unlocking unprecedented potential in observational research, accelerating the development of targeted therapies, and guiding regulatory and reimbursement strategies across markets.

What Technological and Infrastructure Advances Are Enabling the Use of Genomic RWE?

The integration of genomic data into RWE applications is heavily dependent on infrastructure readiness, technological interoperability, and advanced analytics. At the core are high-throughput sequencing platforms that generate extensive genomic profiles, including whole-genome, whole-exome, and targeted sequencing. These genomic data sets are then linked with longitudinal patient data using privacy-preserving record linkage technologies and cloud-based data lakes designed to store and harmonize heterogeneous data types. Cloud infrastructure, particularly through partnerships with providers like AWS, Google Cloud, and Microsoft Azure, allows scalable and secure access to genomic RWE pipelines. Bioinformatics tools and artificial intelligence algorithms are central to mining this complex data, enabling identification of genotype-phenotype correlations, population-specific variant analysis, and real-time evidence generation from decentralized data sources. Federated learning models are also gaining traction, allowing institutions to collaborate on RWE studies without moving sensitive genomic data outside protected environments. Interoperability standards such as FHIR Genomics and OMOP CDM extensions for genomic information are essential for ensuring that these data can be consistently integrated into EHRs, clinical trials, and observational studies. At the institutional level, genomic data warehouses and consent management frameworks are being deployed to ensure patient privacy while facilitating secondary use for research and policy-making. The sophistication of these tools is pushing the boundaries of what can be achieved in RWE, positioning genomics as a foundational layer of future-ready healthcare systems.

How Are End Users Adopting Genomic RWE Across Healthcare and Life Sciences?

The adoption of genomic data sets in RWE applications is expanding across a broad spectrum of end users, including pharmaceutical companies, payers, providers, regulators, and academic institutions. In drug development, biopharma companies are utilizing genomic RWE to optimize clinical trial design through targeted patient recruitment, adaptive trial models, and post-market safety monitoring. By analyzing how specific genetic variants influence treatment responses in diverse, real-world populations, companies can better identify unmet needs, select relevant endpoints, and tailor therapies more precisely. In the payer space, insurers are beginning to rely on genomic RWE to support decisions around value-based contracting, coverage criteria, and precision formulary management. Hospitals and health systems are also incorporating genomic data into clinical decision support tools to enhance diagnostic accuracy and personalize care pathways, particularly in oncology, rare diseases, and pharmacogenomics. Regulators such as the FDA and EMA are embracing genomically-informed RWE to support supplemental approvals, label expansions, and risk-benefit assessments of drugs already in the market. Furthermore, academic researchers are applying these data sets to study real-world gene-environment interactions and population-specific health disparities. Real-world genomics is also being used in public health genomics initiatives, such as surveillance of infectious disease mutations and assessment of vaccine effectiveness. The convergence of stakeholder demand, technological readiness, and policy evolution is driving widespread institutional commitment to embedding genomic RWE across the healthcare continuum.

What Are the Main Drivers Fueling Growth in the Genomic RWE Market?

The growth in the genomic data set for Real World Evidence (RWE) applications market is driven by several factors related to technological advances, shifting healthcare models, data accessibility, and end-user incentives. First, the dramatic reduction in the cost of genomic sequencing has made it feasible to conduct large-scale sequencing of diverse patient cohorts, enabling more representative and inclusive RWE studies. Second, the rise of value-based care and precision medicine models is creating a strong demand for individualized evidence that incorporates genetic data to support better outcomes at lower costs. Third, regulatory bodies are increasingly recognizing genomic RWE as a valid evidence stream for post-market surveillance, accelerated approvals, and drug repurposing efforts, providing a clear incentive for pharmaceutical firms to invest in genomically-enhanced real-world studies. Another major driver is the proliferation of longitudinal bio-banks and national genomics programs that link genomic profiles with lifetime health records, offering rich data environments for observational analysis. Additionally, payer interest in genomics-informed utilization management is growing, particularly in high-cost areas like oncology and rare diseases. The development of interoperable data standards and consent-based data sharing frameworks is also facilitating easier integration and use of genomic RWE in real-world research environments. Furthermore, AI-powered analytics platforms are enabling faster insights and more dynamic hypothesis testing using multi-omic data in real-world populations. Finally, the global expansion of partnerships between tech firms, health systems, and life sciences players is accelerating the commercialization and operationalization of genomic RWE applications. Together, these factors are driving a robust and expanding global market poised to redefine the standards of real-world evidence generation in the precision medicine era.

SCOPE OF STUDY:

The report analyzes the Genomic Data Set for Real World Evidence (RWE) Applications market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Data Type (Genetic DNA Data, Transcriptome RNA Data, Proteome Protein Data, Metabolite Data); Application (Oncology Application, Cardiovascular Application, Neurology Application, Immunology Application, Other Applications); End-Use (Biopharma End-Use, Other End-Uses)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 42 Featured) -

  • 23andMe
  • Aetion Inc.
  • BC Platforms
  • Caris Life Sciences
  • Cegedim Health Data
  • Citeline
  • Clarify Health
  • Cognizant
  • ConcertAI
  • Cytel Inc.
  • Datavant
  • Epigene Labs
  • Flatiron Health
  • Foundation Medicine, Inc.
  • Genuity Science
  • Guardant Health
  • HealthVerity, Inc.
  • Helix
  • ICarbonX
  • Illumina, Inc.

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Tariff Impact on Global Supply Chain Patterns
    • Genomic Data Set for Real World Evidence (RWE) Applications - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Increased Emphasis on Personalized Therapies Drives Use of Genomic RWE for Targeted Interventions
    • Integration of Genomic and Clinical Data Sets Strengthens Business Case for Advanced Evidence Models
    • Regulatory Support for RWE in Drug Approvals Throws Spotlight on Genomic Data Validity
    • Growth in Population Genomics Projects Expands Scope and Depth of Data Repositories
    • Adoption of Genomic RWE in Post-Marketing Surveillance Accelerates Market Expansion
    • Partnerships Between Biobanks, Payers, and Pharma Drive Standardization of Genomic Evidence
    • Advances in Data Curation and Interoperability Tools Enhance Accessibility of Genomic Insights
    • Use of AI and Machine Learning Propels Predictive Modeling Based on Genomic RWE
    • Patient Advocacy and Data Ownership Trends Create Demand for Transparent Usage Models
    • Healthcare Systems Shift Toward Outcome-Based Payments Supports Integration of RWE
    • Concerns Over Genomic Data Privacy and Security Shape Governance Frameworks and Partnerships
    • Global Health Initiatives and Rare Disease Research Sustain Investment in RWE-Ready Genomic Data
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Genomic Data Set for Real World Evidence (RWE) Applications Market Analysis of Annual Sales in US$ Thousand for Years 2014 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Genomic Data Set for Real World Evidence (RWE) Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Genomic Data Set for Real World Evidence (RWE) Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 4: World 16-Year Perspective for Genomic Data Set for Real World Evidence (RWE) Applications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Genetic DNA Data by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Genetic DNA Data by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 7: World 16-Year Perspective for Genetic DNA Data by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Transcriptome RNA Data by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Transcriptome RNA Data by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 10: World 16-Year Perspective for Transcriptome RNA Data by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Proteome Protein Data by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Proteome Protein Data by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 13: World 16-Year Perspective for Proteome Protein Data by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Metabolite Data by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Metabolite Data by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 16: World 16-Year Perspective for Metabolite Data by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Biopharma End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Biopharma End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 19: World 16-Year Perspective for Biopharma End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 22: World 16-Year Perspective for Other End-Uses by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Oncology Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 24: World Historic Review for Oncology Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 25: World 16-Year Perspective for Oncology Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 26: World Recent Past, Current & Future Analysis for Cardiovascular Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 27: World Historic Review for Cardiovascular Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 28: World 16-Year Perspective for Cardiovascular Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 29: World Recent Past, Current & Future Analysis for Neurology Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 30: World Historic Review for Neurology Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 31: World 16-Year Perspective for Neurology Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 32: World Recent Past, Current & Future Analysis for Immunology Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 33: World Historic Review for Immunology Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 34: World 16-Year Perspective for Immunology Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 35: World Recent Past, Current & Future Analysis for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 36: World Historic Review for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 37: World 16-Year Perspective for Other Applications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Genomic Data Set for Real World Evidence (RWE) Applications Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 38: USA Recent Past, Current & Future Analysis for Genomic Data Set for Real World Evidence (RWE) Applications by Data Type - Genetic DNA Data, Transcriptome RNA Data, Proteome Protein Data and Metabolite Data - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 39: USA Historic Review for Genomic Data Set for Real World Evidence (RWE) Applications by Data Type - Genetic DNA Data, Transcriptome RNA Data, Proteome Protein Data and Metabolite Data Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 40: USA 16-Year Perspective for Genomic Data Set for Real World Evidence (RWE) Applications by Data Type - Percentage Breakdown of Value Sales for Genetic DNA Data, Transcriptome RNA Data, Proteome Protein Data and Metabolite Data for the Years 2014, 2025 & 2030
    • TABLE 41: USA Recent Past, Current & Future Analysis for Genomic Data Set for Real World Evidence (RWE) Applications by End-Use - Biopharma End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 42: USA Historic Review for Genomic Data Set for Real World Evidence (RWE) Applications by End-Use - Biopharma End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 43: USA 16-Year Perspective for Genomic Data Set for Real World Evidence (RWE) Applications by End-Use - Percentage Breakdown of Value Sales for Biopharma End-Use and Other End-Uses for the Years 2014, 2025 & 2030
    • TABLE 44: USA Recent Past, Current & Future Analysis for Genomic Data Set for Real World Evidence (RWE) Applications by Application - Oncology Application, Cardiovascular Application, Neurology Application, Immunology Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 45: USA Historic Review for Genomic Data Set for Real World Evidence (RWE) Applications by Application - Oncology Application, Cardiovascular Application, Neurology Application, Immunology Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 46: USA 16-Year Perspective for Genomic Data Set for Real World Evidence (RWE) Applications by Application - Percentage Breakdown of Value Sales for Oncology Application, Cardiovascular Application, Neurology Application, Immunology Application and Other Applications for the Years 2014, 2025 & 2030
  • CANADA
    • TABLE 47: Canada Recent Past, Current & Future Analysis for Genomic Data Set for Real World Evidence (RWE) Applications by Data Type - Genetic DNA Data, Transcriptome RNA Data, Proteome Protein Data and Metabolite Data - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 48: Canada Historic Review for Genomic Data Set for Real World Evidence (RWE) Applications by Data Type - Genetic DNA Data, Transcriptome RNA Data, Proteome Protein Data and Metabolite Data Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 49: Canada 16-Year Perspective for Genomic Data Set for Real World Evidence (RWE) Applications by Data Type - Percentage Breakdown of Value Sales for Genetic DNA Data, Transcriptome RNA Data, Proteome Protein Data and Metabolite Data for the Years 2014, 2025 & 2030
    • TABLE 50: Canada Recent Past, Current & Future Analysis for Genomic Data Set for Real World Evidence (RWE) Applications by End-Use - Biopharma End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 51: Canada Historic Review for Genomic Data Set for Real World Evidence (RWE) Applications by End-Use - Biopharma End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 52: Canada 16-Year Perspective for Genomic Data Set for Real World Evidence (RWE) Applications by End-Use - Percentage Breakdown of Value Sales for Biopharma End-Use and Other End-Uses for the Years 2014, 2025 & 2030
    • TABLE 53: Canada Recent Past, Current & Future Analysis for Genomic Data Set for Real World Evidence (RWE) Applications by Application - Oncology Application, Cardiovascular Application, Neurology Application, Immunology Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 54: Canada Historic Review for Genomic Data Set for Real World Evidence (RWE) Applications by Application - Oncology Application, Cardiovascular Application, Neurology Application, Immunology Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 55: Canada 16-Year Perspective for Genomic Data Set for Real World Evidence (RWE) Applications by Application - Percentage Breakdown of Value Sales for Oncology Application, Cardiovascular Application, Neurology Application, Immunology Application and Other Applications for the Years 2014, 2025 & 2030
  • JAPAN
    • Genomic Data Set for Real World Evidence (RWE) Applications Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 56: Japan Recent Past, Current & Future Analysis for Genomic Data Set for Real World Evidence (RWE) Applications by Data Type - Genetic DNA Data, Transcriptome RNA Data, Proteome Protein Data and Metabolite Data - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 57: Japan Historic Review for Genomic Data Set for Real World Evidence (RWE) Applications by Data Type - Genetic DNA Data, Transcriptome RNA Data, Proteome Protein Data and Metabolite Data Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 58: Japan 16-Year Perspective for Genomic Data Set for Real World Evidence (RWE) Applications by Data Type - Percentage Breakdown of Value Sales for Genetic DNA Data, Transcriptome RNA Data, Proteome Protein Data and Metabolite Data for the Years 2014, 2025 & 2030
    • TABLE 59: Japan Recent Past, Current & Future Analysis for Genomic Data Set for Real World Evidence (RWE) Applications by End-Use - Biopharma End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 60: Japan Historic Review for Genomic Data Set for Real World Evidence (RWE) Applications by End-Use - Biopharma End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 61: Japan 16-Year Perspective for Genomic Data Set for Real World Evidence (RWE) Applications by End-Use - Percentage Breakdown of Value Sales for Biopharma End-Use and Other End-Uses for the Years 2014, 2025 & 2030
    • TABLE 62: Japan Recent Past, Current & Future Analysis for Genomic Data Set for Real World Evidence (RWE) Applications by Application - Oncology Application, Cardiovascular Application, Neurology Application, Immunology Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 63: Japan Historic Review for Genomic Data Set for Real World Evidence (RWE) Applications by Application - Oncology Application, Cardiovascular Application, Neurology Application, Immunology Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 64: Japan 16-Year Perspective for Genomic Data Set for Real World Evidence (RWE) Applications by Application - Percentage Breakdown of Value Sales for Oncology Application, Cardiovascular Application, Neurology Application, Immunology Application and Other Applications for the Years 2014, 2025 & 2030
  • CHINA
    • Genomic Data Set for Real World Evidence (RWE) Applications Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 65: China Recent Past, Current & Future Analysis for Genomic Data Set for Real World Evidence (RWE) Applications by Data Type - Genetic DNA Data, Transcriptome RNA Data, Proteome Protein Data and Metabolite Data - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 66: China Historic Review for Genomic Data Set for Real World Evidence (RWE) Applications by Data Type - Genetic DNA Data, Transcriptome RNA Data, Proteome Protein Data and Metabolite Data Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 67: China 16-Year Perspective for Genomic Data Set for Real World Evidence (RWE) Applications by Data Type - Percentage Breakdown of Value Sales for Genetic DNA Data, Transcriptome RNA Data, Proteome Protein Data and Metabolite Data for the Years 2014, 2025 & 2030
    • TABLE 68: China Recent Past, Current & Future Analysis for Genomic Data Set for Real World Evidence (RWE) Applications by End-Use - Biopharma End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 69: China Historic Review for Genomic Data Set for Real World Evidence (RWE) Applications by End-Use - Biopharma End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 70: China 16-Year Perspective for Genomic Data Set for Real World Evidence (RWE) Applications by End-Use - Percentage Breakdown of Value Sales for Biopharma End-Use and Other End-Uses for the Years 2014, 2025 & 2030
    • TABLE 71: China Recent Past, Current & Future Analysis for Genomic Data Set for Real World Evidence (RWE) Applications by Application - Oncology Application, Cardiovascular Application, Neurology Application, Immunology Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 72: China Historic Review for Genomic Data Set for Real World Evidence (RWE) Applications by Application - Oncology Application, Cardiovascular Application, Neurology Application, Immunology Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 73: China 16-Year Perspective for Genomic Data Set for Real World Evidence (RWE) Applications by Application - Percentage Breakdown of Value Sales for Oncology Application, Cardiovascular Application, Neurology Application, Immunology Application and Other Applications for the Years 2014, 2025 & 2030
  • EUROPE
    • Genomic Data Set for Real World Evidence (RWE) Applications Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 74: Europe Recent Past, Current & Future Analysis for Genomic Data Set for Real World Evidence (RWE) Applications by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 75: Europe Historic Review for Genomic Data Set for Real World Evidence (RWE) Applications by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 76: Europe 16-Year Perspective for Genomic Data Set for Real World Evidence (RWE) Applications by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2025 & 2030
    • TABLE 77: Europe Recent Past, Current & Future Analysis for Genomic Data Set for Real World Evidence (RWE) Applications by Data Type - Genetic DNA Data, Transcriptome RNA Data, Proteome Protein Data and Metabolite Data - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 78: Europe Historic Review for Genomic Data Set for Real World Evidence (RWE) Applications by Data Type - Genetic DNA Data, Transcriptome RNA Data, Proteome Protein Data and Metabolite Data Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 79: Europe 16-Year Perspective for Genomic Data Set for Real World Evidence (RWE) Applications by Data Type - Percentage Breakdown of Value Sales for Genetic DNA Data, Transcriptome RNA Data, Proteome Protein Data and Metabolite Data for the Years 2014, 2025 & 2030
    • TABLE 80: Europe Recent Past, Current & Future Analysis for Genomic Data Set for Real World Evidence (RWE) Applications by End-Use - Biopharma End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 81: Europe Historic Review for Genomic Data Set for Real World Evidence (RWE) Applications by End-Use - Biopharma End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 82: Europe 16-Year Perspective for Genomic Data Set for Real World Evidence (RWE) Applications by End-Use - Percentage Breakdown of Value Sales for Biopharma End-Use and Other End-Uses for the Years 2014, 2025 & 2030
    • TABLE 83: Europe Recent Past, Current & Future Analysis for Genomic Data Set for Real World Evidence (RWE) Applications by Application - Oncology Application, Cardiovascular Application, Neurology Application, Immunology Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 84: Europe Historic Review for Genomic Data Set for Real World Evidence (RWE) Applications by Application - Oncology Application, Cardiovascular Application, Neurology Application, Immunology Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 85: Europe 16-Year Perspective for Genomic Data Set for Real World Evidence (RWE) Applications by Application - Percentage Breakdown of Value Sales for Oncology Application, Cardiovascular Application, Neurology Application, Immunology Application and Other Applications for the Years 2014, 2025 & 2030
  • FRANCE
    • Genomic Data Set for Real World Evidence (RWE) Applications Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 86: France Recent Past, Current & Future Analysis for Genomic Data Set for Real World Evidence (RWE) Applications by Data Type - Genetic DNA Data, Transcriptome RNA Data, Proteome Protein Data and Metabolite Data - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 87: France Historic Review for Genomic Data Set for Real World Evidence (RWE) Applications by Data Type - Genetic DNA Data, Transcriptome RNA Data, Proteome Protein Data and Metabolite Data Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 88: France 16-Year Perspective for Genomic Data Set for Real World Evidence (RWE) Applications by Data Type - Percentage Breakdown of Value Sales for Genetic DNA Data, Transcriptome RNA Data, Proteome Protein Data and Metabolite Data for the Years 2014, 2025 & 2030
    • TABLE 89: France Recent Past, Current & Future Analysis for Genomic Data Set for Real World Evidence (RWE) Applications by End-Use - Biopharma End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 90: France Historic Review for Genomic Data Set for Real World Evidence (RWE) Applications by End-Use - Biopharma End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 91: France 16-Year Perspective for Genomic Data Set for Real World Evidence (RWE) Applications by End-Use - Percentage Breakdown of Value Sales for Biopharma End-Use and Other End-Uses for the Years 2014, 2025 & 2030
    • TABLE 92: France Recent Past, Current & Future Analysis for Genomic Data Set for Real World Evidence (RWE) Applications by Application - Oncology Application, Cardiovascular Application, Neurology Application, Immunology Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 93: France Historic Review for Genomic Data Set for Real World Evidence (RWE) Applications by Application - Oncology Application, Cardiovascular Application, Neurology Application, Immunology Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 94: France 16-Year Perspective for Genomic Data Set for Real World Evidence (RWE) Applications by Application - Percentage Breakdown of Value Sales for Oncology Application, Cardiovascular Application, Neurology Application, Immunology Application and Other Applications for the Years 2014, 2025 & 2030
  • GERMANY
    • Genomic Data Set for Real World Evidence (RWE) Applications Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 95: Germany Recent Past, Current & Future Analysis for Genomic Data Set for Real World Evidence (RWE) Applications by Data Type - Genetic DNA Data, Transcriptome RNA Data, Proteome Protein Data and Metabolite Data - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 96: Germany Historic Review for Genomic Data Set for Real World Evidence (RWE) Applications by Data Type - Genetic DNA Data, Transcriptome RNA Data, Proteome Protein Data and Metabolite Data Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 97: Germany 16-Year Perspective for Genomic Data Set for Real World Evidence (RWE) Applications by Data Type - Percentage Breakdown of Value Sales for Genetic DNA Data, Transcriptome RNA Data, Proteome Protein Data and Metabolite Data for the Years 2014, 2025 & 2030
    • TABLE 98: Germany Recent Past, Current & Future Analysis for Genomic Data Set for Real World Evidence (RWE) Applications by End-Use - Biopharma End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Germany Historic Review for Genomic Data Set for Real World Evidence (RWE) Applications by End-Use - Biopharma End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 100: Germany 16-Year Perspective for Genomic Data Set for Real World Evidence (RWE) Applications by End-Use - Percentage Breakdown of Value Sales for Biopharma End-Use and Other End-Uses for the Years 2014, 2025 & 2030
    • TABLE 101: Germany Recent Past, Current & Future Analysis for Genomic Data Set for Real World Evidence (RWE) Applications by Application - Oncology Application, Cardiovascular Application, Neurology Application, Immunology Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 102: Germany Historic Review for Genomic Data Set for Real World Evidence (RWE) Applications by Application - Oncology Application, Cardiovascular Application, Neurology Application, Immunology Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 103: Germany 16-Year Perspective for Genomic Data Set for Real World Evidence (RWE) Applications by Application - Percentage Breakdown of Value Sales for Oncology Application, Cardiovascular Application, Neurology Application, Immunology Application and Other Applications for the Years 2014, 2025 & 2030
  • ITALY
    • TABLE 104: Italy Recent Past, Current & Future Analysis for Genomic Data Set for Real World Evidence (RWE) Applications by Data Type - Genetic DNA Data, Transcriptome RNA Data, Proteome Protein Data and Metabolite Data - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 105: Italy Historic Review for Genomic Data Set for Real World Evidence (RWE) Applications by Data Type - Genetic DNA Data, Transcriptome RNA Data, Proteome Protein Data and Metabolite Data Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 106: Italy 16-Year Perspective for Genomic Data Set for Real World Evidence (RWE) Applications by Data Type - Percentage Breakdown of Value Sales for Genetic DNA Data, Transcriptome RNA Data, Proteome Protein Data and Metabolite Data for the Years 2014, 2025 & 2030
    • TABLE 107: Italy Recent Past, Current & Future Analysis for Genomic Data Set for Real World Evidence (RWE) Applications by End-Use - Biopharma End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 108: Italy Historic Review for Genomic Data Set for Real World Evidence (RWE) Applications by End-Use - Biopharma End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 109: Italy 16-Year Perspective for Genomic Data Set for Real World Evidence (RWE) Applications by End-Use - Percentage Breakdown of Value Sales for Biopharma End-Use and Other End-Uses for the Years 2014, 2025 & 2030
    • TABLE 110: Italy Recent Past, Current & Future Analysis for Genomic Data Set for Real World Evidence (RWE) Applications by Application - Oncology Application, Cardiovascular Application, Neurology Application, Immunology Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 111: Italy Historic Review for Genomic Data Set for Real World Evidence (RWE) Applications by Application - Oncology Application, Cardiovascular Application, Neurology Application, Immunology Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 112: Italy 16-Year Perspective for Genomic Data Set for Real World Evidence (RWE) Applications by Application - Percentage Breakdown of Value Sales for Oncology Application, Cardiovascular Application, Neurology Application, Immunology Application and Other Applications for the Years 2014, 2025 & 2030
  • UNITED KINGDOM
    • Genomic Data Set for Real World Evidence (RWE) Applications Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 113: UK Recent Past, Current & Future Analysis for Genomic Data Set for Real World Evidence (RWE) Applications by Data Type - Genetic DNA Data, Transcriptome RNA Data, Proteome Protein Data and Metabolite Data - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 114: UK Historic Review for Genomic Data Set for Real World Evidence (RWE) Applications by Data Type - Genetic DNA Data, Transcriptome RNA Data, Proteome Protein Data and Metabolite Data Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 115: UK 16-Year Perspective for Genomic Data Set for Real World Evidence (RWE) Applications by Data Type - Percentage Breakdown of Value Sales for Genetic DNA Data, Transcriptome RNA Data, Proteome Protein Data and Metabolite Data for the Years 2014, 2025 & 2030
    • TABLE 116: UK Recent Past, Current & Future Analysis for Genomic Data Set for Real World Evidence (RWE) Applications by End-Use - Biopharma End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 117: UK Historic Review for Genomic Data Set for Real World Evidence (RWE) Applications by End-Use - Biopharma End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 118: UK 16-Year Perspective for Genomic Data Set for Real World Evidence (RWE) Applications by End-Use - Percentage Breakdown of Value Sales for Biopharma End-Use and Other End-Uses for the Years 2014, 2025 & 2030
    • TABLE 119: UK Recent Past, Current & Future Analysis for Genomic Data Set for Real World Evidence (RWE) Applications by Application - Oncology Application, Cardiovascular Application, Neurology Application, Immunology Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 120: UK Historic Review for Genomic Data Set for Real World Evidence (RWE) Applications by Application - Oncology Application, Cardiovascular Application, Neurology Application, Immunology Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 121: UK 16-Year Perspective for Genomic Data Set for Real World Evidence (RWE) Applications by Application - Percentage Breakdown of Value Sales for Oncology Application, Cardiovascular Application, Neurology Application, Immunology Application and Other Applications for the Years 2014, 2025 & 2030
  • SPAIN
    • TABLE 122: Spain Recent Past, Current & Future Analysis for Genomic Data Set for Real World Evidence (RWE) Applications by Data Type - Genetic DNA Data, Transcriptome RNA Data, Proteome Protein Data and Metabolite Data - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 123: Spain Historic Review for Genomic Data Set for Real World Evidence (RWE) Applications by Data Type - Genetic DNA Data, Transcriptome RNA Data, Proteome Protein Data and Metabolite Data Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 124: Spain 16-Year Perspective for Genomic Data Set for Real World Evidence (RWE) Applications by Data Type - Percentage Breakdown of Value Sales for Genetic DNA Data, Transcriptome RNA Data, Proteome Protein Data and Metabolite Data for the Years 2014, 2025 & 2030
    • TABLE 125: Spain Recent Past, Current & Future Analysis for Genomic Data Set for Real World Evidence (RWE) Applications by End-Use - Biopharma End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 126: Spain Historic Review for Genomic Data Set for Real World Evidence (RWE) Applications by End-Use - Biopharma End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 127: Spain 16-Year Perspective for Genomic Data Set for Real World Evidence (RWE) Applications by End-Use - Percentage Breakdown of Value Sales for Biopharma End-Use and Other End-Uses for the Years 2014, 2025 & 2030
    • TABLE 128: Spain Recent Past, Current & Future Analysis for Genomic Data Set for Real World Evidence (RWE) Applications by Application - Oncology Application, Cardiovascular Application, Neurology Application, Immunology Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 129: Spain Historic Review for Genomic Data Set for Real World Evidence (RWE) Applications by Application - Oncology Application, Cardiovascular Application, Neurology Application, Immunology Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 130: Spain 16-Year Perspective for Genomic Data Set for Real World Evidence (RWE) Applications by Application - Percentage Breakdown of Value Sales for Oncology Application, Cardiovascular Application, Neurology Application, Immunology Application and Other Applications for the Years 2014, 2025 & 2030
  • RUSSIA
    • TABLE 131: Russia Recent Past, Current & Future Analysis for Genomic Data Set for Real World Evidence (RWE) Applications by Data Type - Genetic DNA Data, Transcriptome RNA Data, Proteome Protein Data and Metabolite Data - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 132: Russia Historic Review for Genomic Data Set for Real World Evidence (RWE) Applications by Data Type - Genetic DNA Data, Transcriptome RNA Data, Proteome Protein Data and Metabolite Data Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 133: Russia 16-Year Perspective for Genomic Data Set for Real World Evidence (RWE) Applications by Data Type - Percentage Breakdown of Value Sales for Genetic DNA Data, Transcriptome RNA Data, Proteome Protein Data and Metabolite Data for the Years 2014, 2025 & 2030
    • TABLE 134: Russia Recent Past, Current & Future Analysis for Genomic Data Set for Real World Evidence (RWE) Applications by End-Use - Biopharma End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 135: Russia Historic Review for Genomic Data Set for Real World Evidence (RWE) Applications by End-Use - Biopharma End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 136: Russia 16-Year Perspective for Genomic Data Set for Real World Evidence (RWE) Applications by End-Use - Percentage Breakdown of Value Sales for Biopharma End-Use and Other End-Uses for the Years 2014, 2025 & 2030
    • TABLE 137: Russia Recent Past, Current & Future Analysis for Genomic Data Set for Real World Evidence (RWE) Applications by Application - Oncology Application, Cardiovascular Application, Neurology Application, Immunology Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 138: Russia Historic Review for Genomic Data Set for Real World Evidence (RWE) Applications by Application - Oncology Application, Cardiovascular Application, Neurology Application, Immunology Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 139: Russia 16-Year Perspective for Genomic Data Set for Real World Evidence (RWE) Applications by Application - Percentage Breakdown of Value Sales for Oncology Application, Cardiovascular Application, Neurology Application, Immunology Application and Other Applications for the Years 2014, 2025 & 2030
  • REST OF EUROPE
    • TABLE 140: Rest of Europe Recent Past, Current & Future Analysis for Genomic Data Set for Real World Evidence (RWE) Applications by Data Type - Genetic DNA Data, Transcriptome RNA Data, Proteome Protein Data and Metabolite Data - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 141: Rest of Europe Historic Review for Genomic Data Set for Real World Evidence (RWE) Applications by Data Type - Genetic DNA Data, Transcriptome RNA Data, Proteome Protein Data and Metabolite Data Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 142: Rest of Europe 16-Year Perspective for Genomic Data Set for Real World Evidence (RWE) Applications by Data Type - Percentage Breakdown of Value Sales for Genetic DNA Data, Transcriptome RNA Data, Proteome Protein Data and Metabolite Data for the Years 2014, 2025 & 2030
    • TABLE 143: Rest of Europe Recent Past, Current & Future Analysis for Genomic Data Set for Real World Evidence (RWE) Applications by End-Use - Biopharma End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 144: Rest of Europe Historic Review for Genomic Data Set for Real World Evidence (RWE) Applications by End-Use - Biopharma End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 145: Rest of Europe 16-Year Perspective for Genomic Data Set for Real World Evidence (RWE) Applications by End-Use - Percentage Breakdown of Value Sales for Biopharma End-Use and Other End-Uses for the Years 2014, 2025 & 2030
    • TABLE 146: Rest of Europe Recent Past, Current & Future Analysis for Genomic Data Set for Real World Evidence (RWE) Applications by Application - Oncology Application, Cardiovascular Application, Neurology Application, Immunology Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 147: Rest of Europe Historic Review for Genomic Data Set for Real World Evidence (RWE) Applications by Application - Oncology Application, Cardiovascular Application, Neurology Application, Immunology Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 148: Rest of Europe 16-Year Perspective for Genomic Data Set for Real World Evidence (RWE) Applications by Application - Percentage Breakdown of Value Sales for Oncology Application, Cardiovascular Application, Neurology Application, Immunology Application and Other Applications for the Years 2014, 2025 & 2030
  • ASIA-PACIFIC
    • Genomic Data Set for Real World Evidence (RWE) Applications Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 149: Asia-Pacific Recent Past, Current & Future Analysis for Genomic Data Set for Real World Evidence (RWE) Applications by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 150: Asia-Pacific Historic Review for Genomic Data Set for Real World Evidence (RWE) Applications by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 151: Asia-Pacific 16-Year Perspective for Genomic Data Set for Real World Evidence (RWE) Applications by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2025 & 2030
    • TABLE 152: Asia-Pacific Recent Past, Current & Future Analysis for Genomic Data Set for Real World Evidence (RWE) Applications by Data Type - Genetic DNA Data, Transcriptome RNA Data, Proteome Protein Data and Metabolite Data - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 153: Asia-Pacific Historic Review for Genomic Data Set for Real World Evidence (RWE) Applications by Data Type - Genetic DNA Data, Transcriptome RNA Data, Proteome Protein Data and Metabolite Data Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 154: Asia-Pacific 16-Year Perspective for Genomic Data Set for Real World Evidence (RWE) Applications by Data Type - Percentage Breakdown of Value Sales for Genetic DNA Data, Transcriptome RNA Data, Proteome Protein Data and Metabolite Data for the Years 2014, 2025 & 2030
    • TABLE 155: Asia-Pacific Recent Past, Current & Future Analysis for Genomic Data Set for Real World Evidence (RWE) Applications by End-Use - Biopharma End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 156: Asia-Pacific Historic Review for Genomic Data Set for Real World Evidence (RWE) Applications by End-Use - Biopharma End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 157: Asia-Pacific 16-Year Perspective for Genomic Data Set for Real World Evidence (RWE) Applications by End-Use - Percentage Breakdown of Value Sales for Biopharma End-Use and Other End-Uses for the Years 2014, 2025 & 2030
    • TABLE 158: Asia-Pacific Recent Past, Current & Future Analysis for Genomic Data Set for Real World Evidence (RWE) Applications by Application - Oncology Application, Cardiovascular Application, Neurology Application, Immunology Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 159: Asia-Pacific Historic Review for Genomic Data Set for Real World Evidence (RWE) Applications by Application - Oncology Application, Cardiovascular Application, Neurology Application, Immunology Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 160: Asia-Pacific 16-Year Perspective for Genomic Data Set for Real World Evidence (RWE) Applications by Application - Percentage Breakdown of Value Sales for Oncology Application, Cardiovascular Application, Neurology Application, Immunology Application and Other Applications for the Years 2014, 2025 & 2030
  • AUSTRALIA
    • Genomic Data Set for Real World Evidence (RWE) Applications Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 161: Australia Recent Past, Current & Future Analysis for Genomic Data Set for Real World Evidence (RWE) Applications by Data Type - Genetic DNA Data, Transcriptome RNA Data, Proteome Protein Data and Metabolite Data - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 162: Australia Historic Review for Genomic Data Set for Real World Evidence (RWE) Applications by Data Type - Genetic DNA Data, Transcriptome RNA Data, Proteome Protein Data and Metabolite Data Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 163: Australia 16-Year Perspective for Genomic Data Set for Real World Evidence (RWE) Applications by Data Type - Percentage Breakdown of Value Sales for Genetic DNA Data, Transcriptome RNA Data, Proteome Protein Data and Metabolite Data for the Years 2014, 2025 & 2030
    • TABLE 164: Australia Recent Past, Current & Future Analysis for Genomic Data Set for Real World Evidence (RWE) Applications by End-Use - Biopharma End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 165: Australia Historic Review for Genomic Data Set for Real World Evidence (RWE) Applications by End-Use - Biopharma End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 166: Australia 16-Year Perspective for Genomic Data Set for Real World Evidence (RWE) Applications by End-Use - Percentage Breakdown of Value Sales for Biopharma End-Use and Other End-Uses for the Years 2014, 2025 & 2030
    • TABLE 167: Australia Recent Past, Current & Future Analysis for Genomic Data Set for Real World Evidence (RWE) Applications by Application - Oncology Application, Cardiovascular Application, Neurology Application, Immunology Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 168: Australia Historic Review for Genomic Data Set for Real World Evidence (RWE) Applications by Application - Oncology Application, Cardiovascular Application, Neurology Application, Immunology Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 169: Australia 16-Year Perspective for Genomic Data Set for Real World Evidence (RWE) Applications by Application - Percentage Breakdown of Value Sales for Oncology Application, Cardiovascular Application, Neurology Application, Immunology Application and Other Applications for the Years 2014, 2025 & 2030
  • INDIA
    • Genomic Data Set for Real World Evidence (RWE) Applications Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 170: India Recent Past, Current & Future Analysis for Genomic Data Set for Real World Evidence (RWE) Applications by Data Type - Genetic DNA Data, Transcriptome RNA Data, Proteome Protein Data and Metabolite Data - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 171: India Historic Review for Genomic Data Set for Real World Evidence (RWE) Applications by Data Type - Genetic DNA Data, Transcriptome RNA Data, Proteome Protein Data and Metabolite Data Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 172: India 16-Year Perspective for Genomic Data Set for Real World Evidence (RWE) Applications by Data Type - Percentage Breakdown of Value Sales for Genetic DNA Data, Transcriptome RNA Data, Proteome Protein Data and Metabolite Data for the Years 2014, 2025 & 2030
    • TABLE 173: India Recent Past, Current & Future Analysis for Genomic Data Set for Real World Evidence (RWE) Applications by End-Use - Biopharma End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 174: India Historic Review for Genomic Data Set for Real World Evidence (RWE) Applications by End-Use - Biopharma End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 175: India 16-Year Perspective for Genomic Data Set for Real World Evidence (RWE) Applications by End-Use - Percentage Breakdown of Value Sales for Biopharma End-Use and Other End-Uses for the Years 2014, 2025 & 2030
    • TABLE 176: India Recent Past, Current & Future Analysis for Genomic Data Set for Real World Evidence (RWE) Applications by Application - Oncology Application, Cardiovascular Application, Neurology Application, Immunology Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 177: India Historic Review for Genomic Data Set for Real World Evidence (RWE) Applications by Application - Oncology Application, Cardiovascular Application, Neurology Application, Immunology Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 178: India 16-Year Perspective for Genomic Data Set for Real World Evidence (RWE) Applications by Application - Percentage Breakdown of Value Sales for Oncology Application, Cardiovascular Application, Neurology Application, Immunology Application and Other Applications for the Years 2014, 2025 & 2030
  • SOUTH KOREA
    • TABLE 179: South Korea Recent Past, Current & Future Analysis for Genomic Data Set for Real World Evidence (RWE) Applications by Data Type - Genetic DNA Data, Transcriptome RNA Data, Proteome Protein Data and Metabolite Data - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 180: South Korea Historic Review for Genomic Data Set for Real World Evidence (RWE) Applications by Data Type - Genetic DNA Data, Transcriptome RNA Data, Proteome Protein Data and Metabolite Data Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 181: South Korea 16-Year Perspective for Genomic Data Set for Real World Evidence (RWE) Applications by Data Type - Percentage Breakdown of Value Sales for Genetic DNA Data, Transcriptome RNA Data, Proteome Protein Data and Metabolite Data for the Years 2014, 2025 & 2030
    • TABLE 182: South Korea Recent Past, Current & Future Analysis for Genomic Data Set for Real World Evidence (RWE) Applications by End-Use - Biopharma End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 183: South Korea Historic Review for Genomic Data Set for Real World Evidence (RWE) Applications by End-Use - Biopharma End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 184: South Korea 16-Year Perspective for Genomic Data Set for Real World Evidence (RWE) Applications by End-Use - Percentage Breakdown of Value Sales for Biopharma End-Use and Other End-Uses for the Years 2014, 2025 & 2030
    • TABLE 185: South Korea Recent Past, Current & Future Analysis for Genomic Data Set for Real World Evidence (RWE) Applications by Application - Oncology Application, Cardiovascular Application, Neurology Application, Immunology Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 186: South Korea Historic Review for Genomic Data Set for Real World Evidence (RWE) Applications by Application - Oncology Application, Cardiovascular Application, Neurology Application, Immunology Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 187: South Korea 16-Year Perspective for Genomic Data Set for Real World Evidence (RWE) Applications by Application - Percentage Breakdown of Value Sales for Oncology Application, Cardiovascular Application, Neurology Application, Immunology Application and Other Applications for the Years 2014, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 188: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Genomic Data Set for Real World Evidence (RWE) Applications by Data Type - Genetic DNA Data, Transcriptome RNA Data, Proteome Protein Data and Metabolite Data - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 189: Rest of Asia-Pacific Historic Review for Genomic Data Set for Real World Evidence (RWE) Applications by Data Type - Genetic DNA Data, Transcriptome RNA Data, Proteome Protein Data and Metabolite Data Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 190: Rest of Asia-Pacific 16-Year Perspective for Genomic Data Set for Real World Evidence (RWE) Applications by Data Type - Percentage Breakdown of Value Sales for Genetic DNA Data, Transcriptome RNA Data, Proteome Protein Data and Metabolite Data for the Years 2014, 2025 & 2030
    • TABLE 191: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Genomic Data Set for Real World Evidence (RWE) Applications by End-Use - Biopharma End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 192: Rest of Asia-Pacific Historic Review for Genomic Data Set for Real World Evidence (RWE) Applications by End-Use - Biopharma End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 193: Rest of Asia-Pacific 16-Year Perspective for Genomic Data Set for Real World Evidence (RWE) Applications by End-Use - Percentage Breakdown of Value Sales for Biopharma End-Use and Other End-Uses for the Years 2014, 2025 & 2030
    • TABLE 194: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Genomic Data Set for Real World Evidence (RWE) Applications by Application - Oncology Application, Cardiovascular Application, Neurology Application, Immunology Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 195: Rest of Asia-Pacific Historic Review for Genomic Data Set for Real World Evidence (RWE) Applications by Application - Oncology Application, Cardiovascular Application, Neurology Application, Immunology Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 196: Rest of Asia-Pacific 16-Year Perspective for Genomic Data Set for Real World Evidence (RWE) Applications by Application - Percentage Breakdown of Value Sales for Oncology Application, Cardiovascular Application, Neurology Application, Immunology Application and Other Applications for the Years 2014, 2025 & 2030
  • LATIN AMERICA
    • Genomic Data Set for Real World Evidence (RWE) Applications Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 197: Latin America Recent Past, Current & Future Analysis for Genomic Data Set for Real World Evidence (RWE) Applications by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 198: Latin America Historic Review for Genomic Data Set for Real World Evidence (RWE) Applications by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 199: Latin America 16-Year Perspective for Genomic Data Set for Real World Evidence (RWE) Applications by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2025 & 2030
    • TABLE 200: Latin America Recent Past, Current & Future Analysis for Genomic Data Set for Real World Evidence (RWE) Applications by Data Type - Genetic DNA Data, Transcriptome RNA Data, Proteome Protein Data and Metabolite Data - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 201: Latin America Historic Review for Genomic Data Set for Real World Evidence (RWE) Applications by Data Type - Genetic DNA Data, Transcriptome RNA Data, Proteome Protein Data and Metabolite Data Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 202: Latin America 16-Year Perspective for Genomic Data Set for Real World Evidence (RWE) Applications by Data Type - Percentage Breakdown of Value Sales for Genetic DNA Data, Transcriptome RNA Data, Proteome Protein Data and Metabolite Data for the Years 2014, 2025 & 2030
    • TABLE 203: Latin America Recent Past, Current & Future Analysis for Genomic Data Set for Real World Evidence (RWE) Applications by End-Use - Biopharma End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 204: Latin America Historic Review for Genomic Data Set for Real World Evidence (RWE) Applications by End-Use - Biopharma End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 205: Latin America 16-Year Perspective for Genomic Data Set for Real World Evidence (RWE) Applications by End-Use - Percentage Breakdown of Value Sales for Biopharma End-Use and Other End-Uses for the Years 2014, 2025 & 2030
    • TABLE 206: Latin America Recent Past, Current & Future Analysis for Genomic Data Set for Real World Evidence (RWE) Applications by Application - Oncology Application, Cardiovascular Application, Neurology Application, Immunology Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 207: Latin America Historic Review for Genomic Data Set for Real World Evidence (RWE) Applications by Application - Oncology Application, Cardiovascular Application, Neurology Application, Immunology Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 208: Latin America 16-Year Perspective for Genomic Data Set for Real World Evidence (RWE) Applications by Application - Percentage Breakdown of Value Sales for Oncology Application, Cardiovascular Application, Neurology Application, Immunology Application and Other Applications for the Years 2014, 2025 & 2030
  • ARGENTINA
    • TABLE 209: Argentina Recent Past, Current & Future Analysis for Genomic Data Set for Real World Evidence (RWE) Applications by Data Type - Genetic DNA Data, Transcriptome RNA Data, Proteome Protein Data and Metabolite Data - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 210: Argentina Historic Review for Genomic Data Set for Real World Evidence (RWE) Applications by Data Type - Genetic DNA Data, Transcriptome RNA Data, Proteome Protein Data and Metabolite Data Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 211: Argentina 16-Year Perspective for Genomic Data Set for Real World Evidence (RWE) Applications by Data Type - Percentage Breakdown of Value Sales for Genetic DNA Data, Transcriptome RNA Data, Proteome Protein Data and Metabolite Data for the Years 2014, 2025 & 2030
    • TABLE 212: Argentina Recent Past, Current & Future Analysis for Genomic Data Set for Real World Evidence (RWE) Applications by End-Use - Biopharma End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 213: Argentina Historic Review for Genomic Data Set for Real World Evidence (RWE) Applications by End-Use - Biopharma End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 214: Argentina 16-Year Perspective for Genomic Data Set for Real World Evidence (RWE) Applications by End-Use - Percentage Breakdown of Value Sales for Biopharma End-Use and Other End-Uses for the Years 2014, 2025 & 2030
    • TABLE 215: Argentina Recent Past, Current & Future Analysis for Genomic Data Set for Real World Evidence (RWE) Applications by Application - Oncology Application, Cardiovascular Application, Neurology Application, Immunology Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 216: Argentina Historic Review for Genomic Data Set for Real World Evidence (RWE) Applications by Application - Oncology Application, Cardiovascular Application, Neurology Application, Immunology Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 217: Argentina 16-Year Perspective for Genomic Data Set for Real World Evidence (RWE) Applications by Application - Percentage Breakdown of Value Sales for Oncology Application, Cardiovascular Application, Neurology Application, Immunology Application and Other Applications for the Years 2014, 2025 & 2030
  • BRAZIL
    • TABLE 218: Brazil Recent Past, Current & Future Analysis for Genomic Data Set for Real World Evidence (RWE) Applications by Data Type - Genetic DNA Data, Transcriptome RNA Data, Proteome Protein Data and Metabolite Data - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 219: Brazil Historic Review for Genomic Data Set for Real World Evidence (RWE) Applications by Data Type - Genetic DNA Data, Transcriptome RNA Data, Proteome Protein Data and Metabolite Data Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 220: Brazil 16-Year Perspective for Genomic Data Set for Real World Evidence (RWE) Applications by Data Type - Percentage Breakdown of Value Sales for Genetic DNA Data, Transcriptome RNA Data, Proteome Protein Data and Metabolite Data for the Years 2014, 2025 & 2030
    • TABLE 221: Brazil Recent Past, Current & Future Analysis for Genomic Data Set for Real World Evidence (RWE) Applications by End-Use - Biopharma End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 222: Brazil Historic Review for Genomic Data Set for Real World Evidence (RWE) Applications by End-Use - Biopharma End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 223: Brazil 16-Year Perspective for Genomic Data Set for Real World Evidence (RWE) Applications by End-Use - Percentage Breakdown of Value Sales for Biopharma End-Use and Other End-Uses for the Years 2014, 2025 & 2030
    • TABLE 224: Brazil Recent Past, Current & Future Analysis for Genomic Data Set for Real World Evidence (RWE) Applications by Application - Oncology Application, Cardiovascular Application, Neurology Application, Immunology Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 225: Brazil Historic Review for Genomic Data Set for Real World Evidence (RWE) Applications by Application - Oncology Application, Cardiovascular Application, Neurology Application, Immunology Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 226: Brazil 16-Year Perspective for Genomic Data Set for Real World Evidence (RWE) Applications by Application - Percentage Breakdown of Value Sales for Oncology Application, Cardiovascular Application, Neurology Application, Immunology Application and Other Applications for the Years 2014, 2025 & 2030
  • MEXICO
    • TABLE 227: Mexico Recent Past, Current & Future Analysis for Genomic Data Set for Real World Evidence (RWE) Applications by Data Type - Genetic DNA Data, Transcriptome RNA Data, Proteome Protein Data and Metabolite Data - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 228: Mexico Historic Review for Genomic Data Set for Real World Evidence (RWE) Applications by Data Type - Genetic DNA Data, Transcriptome RNA Data, Proteome Protein Data and Metabolite Data Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 229: Mexico 16-Year Perspective for Genomic Data Set for Real World Evidence (RWE) Applications by Data Type - Percentage Breakdown of Value Sales for Genetic DNA Data, Transcriptome RNA Data, Proteome Protein Data and Metabolite Data for the Years 2014, 2025 & 2030
    • TABLE 230: Mexico Recent Past, Current & Future Analysis for Genomic Data Set for Real World Evidence (RWE) Applications by End-Use - Biopharma End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 231: Mexico Historic Review for Genomic Data Set for Real World Evidence (RWE) Applications by End-Use - Biopharma End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 232: Mexico 16-Year Perspective for Genomic Data Set for Real World Evidence (RWE) Applications by End-Use - Percentage Breakdown of Value Sales for Biopharma End-Use and Other End-Uses for the Years 2014, 2025 & 2030
    • TABLE 233: Mexico Recent Past, Current & Future Analysis for Genomic Data Set for Real World Evidence (RWE) Applications by Application - Oncology Application, Cardiovascular Application, Neurology Application, Immunology Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 234: Mexico Historic Review for Genomic Data Set for Real World Evidence (RWE) Applications by Application - Oncology Application, Cardiovascular Application, Neurology Application, Immunology Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 235: Mexico 16-Year Perspective for Genomic Data Set for Real World Evidence (RWE) Applications by Application - Percentage Breakdown of Value Sales for Oncology Application, Cardiovascular Application, Neurology Application, Immunology Application and Other Applications for the Years 2014, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 236: Rest of Latin America Recent Past, Current & Future Analysis for Genomic Data Set for Real World Evidence (RWE) Applications by Data Type - Genetic DNA Data, Transcriptome RNA Data, Proteome Protein Data and Metabolite Data - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 237: Rest of Latin America Historic Review for Genomic Data Set for Real World Evidence (RWE) Applications by Data Type - Genetic DNA Data, Transcriptome RNA Data, Proteome Protein Data and Metabolite Data Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 238: Rest of Latin America 16-Year Perspective for Genomic Data Set for Real World Evidence (RWE) Applications by Data Type - Percentage Breakdown of Value Sales for Genetic DNA Data, Transcriptome RNA Data, Proteome Protein Data and Metabolite Data for the Years 2014, 2025 & 2030
    • TABLE 239: Rest of Latin America Recent Past, Current & Future Analysis for Genomic Data Set for Real World Evidence (RWE) Applications by End-Use - Biopharma End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 240: Rest of Latin America Historic Review for Genomic Data Set for Real World Evidence (RWE) Applications by End-Use - Biopharma End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 241: Rest of Latin America 16-Year Perspective for Genomic Data Set for Real World Evidence (RWE) Applications by End-Use - Percentage Breakdown of Value Sales for Biopharma End-Use and Other End-Uses for the Years 2014, 2025 & 2030
    • TABLE 242: Rest of Latin America Recent Past, Current & Future Analysis for Genomic Data Set for Real World Evidence (RWE) Applications by Application - Oncology Application, Cardiovascular Application, Neurology Application, Immunology Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 243: Rest of Latin America Historic Review for Genomic Data Set for Real World Evidence (RWE) Applications by Application - Oncology Application, Cardiovascular Application, Neurology Application, Immunology Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 244: Rest of Latin America 16-Year Perspective for Genomic Data Set for Real World Evidence (RWE) Applications by Application - Percentage Breakdown of Value Sales for Oncology Application, Cardiovascular Application, Neurology Application, Immunology Application and Other Applications for the Years 2014, 2025 & 2030
  • MIDDLE EAST
    • Genomic Data Set for Real World Evidence (RWE) Applications Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 245: Middle East Recent Past, Current & Future Analysis for Genomic Data Set for Real World Evidence (RWE) Applications by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 246: Middle East Historic Review for Genomic Data Set for Real World Evidence (RWE) Applications by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 247: Middle East 16-Year Perspective for Genomic Data Set for Real World Evidence (RWE) Applications by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2025 & 2030
    • TABLE 248: Middle East Recent Past, Current & Future Analysis for Genomic Data Set for Real World Evidence (RWE) Applications by Data Type - Genetic DNA Data, Transcriptome RNA Data, Proteome Protein Data and Metabolite Data - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 249: Middle East Historic Review for Genomic Data Set for Real World Evidence (RWE) Applications by Data Type - Genetic DNA Data, Transcriptome RNA Data, Proteome Protein Data and Metabolite Data Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 250: Middle East 16-Year Perspective for Genomic Data Set for Real World Evidence (RWE) Applications by Data Type - Percentage Breakdown of Value Sales for Genetic DNA Data, Transcriptome RNA Data, Proteome Protein Data and Metabolite Data for the Years 2014, 2025 & 2030
    • TABLE 251: Middle East Recent Past, Current & Future Analysis for Genomic Data Set for Real World Evidence (RWE) Applications by End-Use - Biopharma End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 252: Middle East Historic Review for Genomic Data Set for Real World Evidence (RWE) Applications by End-Use - Biopharma End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 253: Middle East 16-Year Perspective for Genomic Data Set for Real World Evidence (RWE) Applications by End-Use - Percentage Breakdown of Value Sales for Biopharma End-Use and Other End-Uses for the Years 2014, 2025 & 2030
    • TABLE 254: Middle East Recent Past, Current & Future Analysis for Genomic Data Set for Real World Evidence (RWE) Applications by Application - Oncology Application, Cardiovascular Application, Neurology Application, Immunology Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 255: Middle East Historic Review for Genomic Data Set for Real World Evidence (RWE) Applications by Application - Oncology Application, Cardiovascular Application, Neurology Application, Immunology Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 256: Middle East 16-Year Perspective for Genomic Data Set for Real World Evidence (RWE) Applications by Application - Percentage Breakdown of Value Sales for Oncology Application, Cardiovascular Application, Neurology Application, Immunology Application and Other Applications for the Years 2014, 2025 & 2030
  • IRAN
    • TABLE 257: Iran Recent Past, Current & Future Analysis for Genomic Data Set for Real World Evidence (RWE) Applications by Data Type - Genetic DNA Data, Transcriptome RNA Data, Proteome Protein Data and Metabolite Data - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 258: Iran Historic Review for Genomic Data Set for Real World Evidence (RWE) Applications by Data Type - Genetic DNA Data, Transcriptome RNA Data, Proteome Protein Data and Metabolite Data Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 259: Iran 16-Year Perspective for Genomic Data Set for Real World Evidence (RWE) Applications by Data Type - Percentage Breakdown of Value Sales for Genetic DNA Data, Transcriptome RNA Data, Proteome Protein Data and Metabolite Data for the Years 2014, 2025 & 2030
    • TABLE 260: Iran Recent Past, Current & Future Analysis for Genomic Data Set for Real World Evidence (RWE) Applications by End-Use - Biopharma End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 261: Iran Historic Review for Genomic Data Set for Real World Evidence (RWE) Applications by End-Use - Biopharma End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 262: Iran 16-Year Perspective for Genomic Data Set for Real World Evidence (RWE) Applications by End-Use - Percentage Breakdown of Value Sales for Biopharma End-Use and Other End-Uses for the Years 2014, 2025 & 2030
    • TABLE 263: Iran Recent Past, Current & Future Analysis for Genomic Data Set for Real World Evidence (RWE) Applications by Application - Oncology Application, Cardiovascular Application, Neurology Application, Immunology Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 264: Iran Historic Review for Genomic Data Set for Real World Evidence (RWE) Applications by Application - Oncology Application, Cardiovascular Application, Neurology Application, Immunology Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 265: Iran 16-Year Perspective for Genomic Data Set for Real World Evidence (RWE) Applications by Application - Percentage Breakdown of Value Sales for Oncology Application, Cardiovascular Application, Neurology Application, Immunology Application and Other Applications for the Years 2014, 2025 & 2030
  • ISRAEL
    • TABLE 266: Israel Recent Past, Current & Future Analysis for Genomic Data Set for Real World Evidence (RWE) Applications by Data Type - Genetic DNA Data, Transcriptome RNA Data, Proteome Protein Data and Metabolite Data - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 267: Israel Historic Review for Genomic Data Set for Real World Evidence (RWE) Applications by Data Type - Genetic DNA Data, Transcriptome RNA Data, Proteome Protein Data and Metabolite Data Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 268: Israel 16-Year Perspective for Genomic Data Set for Real World Evidence (RWE) Applications by Data Type - Percentage Breakdown of Value Sales for Genetic DNA Data, Transcriptome RNA Data, Proteome Protein Data and Metabolite Data for the Years 2014, 2025 & 2030
    • TABLE 269: Israel Recent Past, Current & Future Analysis for Genomic Data Set for Real World Evidence (RWE) Applications by End-Use - Biopharma End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 270: Israel Historic Review for Genomic Data Set for Real World Evidence (RWE) Applications by End-Use - Biopharma End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 271: Israel 16-Year Perspective for Genomic Data Set for Real World Evidence (RWE) Applications by End-Use - Percentage Breakdown of Value Sales for Biopharma End-Use and Other End-Uses for the Years 2014, 2025 & 2030
    • TABLE 272: Israel Recent Past, Current & Future Analysis for Genomic Data Set for Real World Evidence (RWE) Applications by Application - Oncology Application, Cardiovascular Application, Neurology Application, Immunology Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 273: Israel Historic Review for Genomic Data Set for Real World Evidence (RWE) Applications by Application - Oncology Application, Cardiovascular Application, Neurology Application, Immunology Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 274: Israel 16-Year Perspective for Genomic Data Set for Real World Evidence (RWE) Applications by Application - Percentage Breakdown of Value Sales for Oncology Application, Cardiovascular Application, Neurology Application, Immunology Application and Other Applications for the Years 2014, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 275: Saudi Arabia Recent Past, Current & Future Analysis for Genomic Data Set for Real World Evidence (RWE) Applications by Data Type - Genetic DNA Data, Transcriptome RNA Data, Proteome Protein Data and Metabolite Data - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 276: Saudi Arabia Historic Review for Genomic Data Set for Real World Evidence (RWE) Applications by Data Type - Genetic DNA Data, Transcriptome RNA Data, Proteome Protein Data and Metabolite Data Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 277: Saudi Arabia 16-Year Perspective for Genomic Data Set for Real World Evidence (RWE) Applications by Data Type - Percentage Breakdown of Value Sales for Genetic DNA Data, Transcriptome RNA Data, Proteome Protein Data and Metabolite Data for the Years 2014, 2025 & 2030
    • TABLE 278: Saudi Arabia Recent Past, Current & Future Analysis for Genomic Data Set for Real World Evidence (RWE) Applications by End-Use - Biopharma End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 279: Saudi Arabia Historic Review for Genomic Data Set for Real World Evidence (RWE) Applications by End-Use - Biopharma End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 280: Saudi Arabia 16-Year Perspective for Genomic Data Set for Real World Evidence (RWE) Applications by End-Use - Percentage Breakdown of Value Sales for Biopharma End-Use and Other End-Uses for the Years 2014, 2025 & 2030
    • TABLE 281: Saudi Arabia Recent Past, Current & Future Analysis for Genomic Data Set for Real World Evidence (RWE) Applications by Application - Oncology Application, Cardiovascular Application, Neurology Application, Immunology Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 282: Saudi Arabia Historic Review for Genomic Data Set for Real World Evidence (RWE) Applications by Application - Oncology Application, Cardiovascular Application, Neurology Application, Immunology Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 283: Saudi Arabia 16-Year Perspective for Genomic Data Set for Real World Evidence (RWE) Applications by Application - Percentage Breakdown of Value Sales for Oncology Application, Cardiovascular Application, Neurology Application, Immunology Application and Other Applications for the Years 2014, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 284: UAE Recent Past, Current & Future Analysis for Genomic Data Set for Real World Evidence (RWE) Applications by Data Type - Genetic DNA Data, Transcriptome RNA Data, Proteome Protein Data and Metabolite Data - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 285: UAE Historic Review for Genomic Data Set for Real World Evidence (RWE) Applications by Data Type - Genetic DNA Data, Transcriptome RNA Data, Proteome Protein Data and Metabolite Data Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 286: UAE 16-Year Perspective for Genomic Data Set for Real World Evidence (RWE) Applications by Data Type - Percentage Breakdown of Value Sales for Genetic DNA Data, Transcriptome RNA Data, Proteome Protein Data and Metabolite Data for the Years 2014, 2025 & 2030
    • TABLE 287: UAE Recent Past, Current & Future Analysis for Genomic Data Set for Real World Evidence (RWE) Applications by End-Use - Biopharma End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 288: UAE Historic Review for Genomic Data Set for Real World Evidence (RWE) Applications by End-Use - Biopharma End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 289: UAE 16-Year Perspective for Genomic Data Set for Real World Evidence (RWE) Applications by End-Use - Percentage Breakdown of Value Sales for Biopharma End-Use and Other End-Uses for the Years 2014, 2025 & 2030
    • TABLE 290: UAE Recent Past, Current & Future Analysis for Genomic Data Set for Real World Evidence (RWE) Applications by Application - Oncology Application, Cardiovascular Application, Neurology Application, Immunology Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 291: UAE Historic Review for Genomic Data Set for Real World Evidence (RWE) Applications by Application - Oncology Application, Cardiovascular Application, Neurology Application, Immunology Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 292: UAE 16-Year Perspective for Genomic Data Set for Real World Evidence (RWE) Applications by Application - Percentage Breakdown of Value Sales for Oncology Application, Cardiovascular Application, Neurology Application, Immunology Application and Other Applications for the Years 2014, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 293: Rest of Middle East Recent Past, Current & Future Analysis for Genomic Data Set for Real World Evidence (RWE) Applications by Data Type - Genetic DNA Data, Transcriptome RNA Data, Proteome Protein Data and Metabolite Data - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 294: Rest of Middle East Historic Review for Genomic Data Set for Real World Evidence (RWE) Applications by Data Type - Genetic DNA Data, Transcriptome RNA Data, Proteome Protein Data and Metabolite Data Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 295: Rest of Middle East 16-Year Perspective for Genomic Data Set for Real World Evidence (RWE) Applications by Data Type - Percentage Breakdown of Value Sales for Genetic DNA Data, Transcriptome RNA Data, Proteome Protein Data and Metabolite Data for the Years 2014, 2025 & 2030
    • TABLE 296: Rest of Middle East Recent Past, Current & Future Analysis for Genomic Data Set for Real World Evidence (RWE) Applications by End-Use - Biopharma End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 297: Rest of Middle East Historic Review for Genomic Data Set for Real World Evidence (RWE) Applications by End-Use - Biopharma End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 298: Rest of Middle East 16-Year Perspective for Genomic Data Set for Real World Evidence (RWE) Applications by End-Use - Percentage Breakdown of Value Sales for Biopharma End-Use and Other End-Uses for the Years 2014, 2025 & 2030
    • TABLE 299: Rest of Middle East Recent Past, Current & Future Analysis for Genomic Data Set for Real World Evidence (RWE) Applications by Application - Oncology Application, Cardiovascular Application, Neurology Application, Immunology Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 300: Rest of Middle East Historic Review for Genomic Data Set for Real World Evidence (RWE) Applications by Application - Oncology Application, Cardiovascular Application, Neurology Application, Immunology Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 301: Rest of Middle East 16-Year Perspective for Genomic Data Set for Real World Evidence (RWE) Applications by Application - Percentage Breakdown of Value Sales for Oncology Application, Cardiovascular Application, Neurology Application, Immunology Application and Other Applications for the Years 2014, 2025 & 2030
  • AFRICA
    • Genomic Data Set for Real World Evidence (RWE) Applications Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 302: Africa Recent Past, Current & Future Analysis for Genomic Data Set for Real World Evidence (RWE) Applications by Data Type - Genetic DNA Data, Transcriptome RNA Data, Proteome Protein Data and Metabolite Data - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 303: Africa Historic Review for Genomic Data Set for Real World Evidence (RWE) Applications by Data Type - Genetic DNA Data, Transcriptome RNA Data, Proteome Protein Data and Metabolite Data Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 304: Africa 16-Year Perspective for Genomic Data Set for Real World Evidence (RWE) Applications by Data Type - Percentage Breakdown of Value Sales for Genetic DNA Data, Transcriptome RNA Data, Proteome Protein Data and Metabolite Data for the Years 2014, 2025 & 2030
    • TABLE 305: Africa Recent Past, Current & Future Analysis for Genomic Data Set for Real World Evidence (RWE) Applications by End-Use - Biopharma End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 306: Africa Historic Review for Genomic Data Set for Real World Evidence (RWE) Applications by End-Use - Biopharma End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 307: Africa 16-Year Perspective for Genomic Data Set for Real World Evidence (RWE) Applications by End-Use - Percentage Breakdown of Value Sales for Biopharma End-Use and Other End-Uses for the Years 2014, 2025 & 2030
    • TABLE 308: Africa Recent Past, Current & Future Analysis for Genomic Data Set for Real World Evidence (RWE) Applications by Application - Oncology Application, Cardiovascular Application, Neurology Application, Immunology Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 309: Africa Historic Review for Genomic Data Set for Real World Evidence (RWE) Applications by Application - Oncology Application, Cardiovascular Application, Neurology Application, Immunology Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 310: Africa 16-Year Perspective for Genomic Data Set for Real World Evidence (RWE) Applications by Application - Percentage Breakdown of Value Sales for Oncology Application, Cardiovascular Application, Neurology Application, Immunology Application and Other Applications for the Years 2014, 2025 & 2030

IV. COMPETITION